Endothelial antioxidant actions of dihydropyridines and angiotensin converting enzyme inhibitors

European Journal of Pharmacology

Volumn 529, Issue 1-3, 2006, Pages 55-62

  Rosenkranz, Anke C ^a,c   Lob, Heinrich ^a   Breitenbach, Thomas ^a   Berkels, Reinhard ^b   Roesen, Renate ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c QUEEN ELIZABETH HOSPITAL   (Australia)

Author keywords

Angiotensin converting enzyme inhibitor; Dihydropyridine; Endothelial cell; High glucose; Nitric oxide; Superoxide

Indexed keywords

AMLODIPINE; BAYK 8644; BRADYKININ; BRADYKININ B2 RECEPTOR ANTAGONIST; CAPTOPRIL; CYTOCHROME C; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRILAT; GLUCOSE; LUCIGENIN; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; NIFEDIPINE; NISOLDIPINE; NITRIC OXIDE; RAMIPRILAT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RHODAMINE 123; SUPEROXIDE; UNCLASSIFIED DRUG;

AMPEROMETRIC BIOSENSOR; ANTIOXIDANT ACTIVITY; ARTICLE; BIOAVAILABILITY; CHEMOLUMINESCENCE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIUM; ENZYME INHIBITION; FLUORESCENCE; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIOXIDANTS; CELL LINE; CYTOCHROMES C; DIHYDROPYRIDINES; ENDOTHELIAL CELLS; GLUCOSE; HUMANS; NITRIC OXIDE; SUPEROXIDES;

EID: 29344445466     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2005.10.046     Document Type: Article

References (37)

1. Y. Asano, J. Kim, A. Ogai, S. Takashima, Y. Shintani, T. Minamino, S. Kitamura, H. Tomoike, M. Hori, and M. Kitakaze A calcium channel blocker activates both ecto-5(′)-nucleotidase and NO synthase in HUVEC Biochem. Biophys. Res. Commun. 311 2003 625 628
2. H. Asanuma, M. Kitakaze, K. Node, S. Takashima, Y. Sakata, M. Asakura, S. Sanada, Y. Shinozaki, H. Mori, M. Tada, T. Kuzuya, and M. Hori Benidipine, a long-acting Ca channel blocker, limits infarct size via bradykinin- and NO-dependent mechanisms in canine hearts Cardiovasc. Drugs Ther. 15 2001 225 231
3. Y. Baykal, M.I. Yilmaz, T. Celik, F. Gok, H. Rehber, C. Akay, and I.H. Kocar Effects of antihypertensive agents, alpha receptor blockers, beta blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and calcium channel blockers, on oxidative stress J. Hypertens. 21 2003 1207 1211
4. R. Berkels, G. Egink, T.A. Marsen, H. Bartels, R. Roesen, and W. Klaus Nifedipine increases endothelial nitric oxide bioavailability by antioxidative mechanisms Hypertension 37 2001 240 245
5. R. Berkels, D. Taubert, A. Rosenkranz, and R. Rosen Vascular protective effects of dihydropyridine calcium antagonists. Involvement of endothelial nitric oxide Pharmacology 69 2003 171 176
6. R. Berkels, D. Taubert, H. Bartels, T. Breitenbach, W. Klaus, and R. Roesen Amlodipine increases endothelial nitric oxide by dual mechanisms Pharmacology 70 2004 39 45
7. R. Berkels, T. Breitenbach, H. Bartels, D. Taubert, A. Rosenkranz, W. Klaus, and R. Roesen Different antioxidative potencies of dihydropyridine calcium channel modulators in various models Vasc. Pharmacol. 42 2005 145 152
8. T. Breitenbach, H. Bartels, R. Berkels, W. Klaus, and R. Roesen Antioxidative properties of dihydropyridin-calcium antagonists in comparison with ace-inhibitors Naunyn-Schmiedeberg's Arch. Pharmacol. 367 Suppl. 1 2003 R66 (abstract)
9. L.A. Calo, F. Zaghetto, E. Pagnin, P.A. Davis, A. Semplicini, and A.C. Pessina Effect of manidipine on gene expression and protein level of oxidative stress-related proteins: P22phox and HO-1: relevance for antihypertensive and anti-remodeling effects J. Cardiovasc. Pharmacol. 43 2004 531 538
10. A. Ceriello, and E. Motz Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited Arterioscler. Thromb. Vasc. Biol. 24 2004 816 823
11. R. Chen, M. Iwai, L. Wu, J. Suzuki, L.J. Min, T. Shiuchi, T. Sugaya, H.W. Liu, T.X. Cui, and M. Horiuchi Important role of nitric oxide in the effect of angiotensin-converting enzyme inhibitor imidapril on vascular injury Hypertension 42 2003 542 547
12. L. Cominacini, A. Fratta Pasini, U. Garbin, A.M. Pastorino, A. Davoli, C. Nava, M. Campagnola, P. Rossato, and V. Lo Cascio Antioxidant activity of different dihydropyridines Biochem. Biophys. Res. Commun. 302 2003 679 684
13. E.M. de Cavanagh, F. Inserra, J. Toblli, I. Stella, C.G. Fraga, and L. Ferder Enalapril attenuates oxidative stress in diabetic rats Hypertension 38 2001 1130 1136
14. A. Hempel, C. Lindschau, C. Maasch, M. Mahn, R. Bychkov, T. Noll, F.C. Luft, and H. Haller Calcium antagonists ameliorate ischemia-induced endothelial cell permeability by inhibiting protein kinase C Circulation 99 1999 2523 2529
15. L.G. Herbette, D.G. Rhodes, and R.P. Mason New approaches to drug design and delivery based on drug-membrane interactions Drug Des. Deliv. 7 1991 75 118
16. T. Inoguchi, T. Sonta, H. Tsubouchi, T. Etoh, M. Kakimoto, N. Sonoda, N. Sato, N. Sekiguchi, K. Kobayashi, H. Sumimoto, H. Utsumi, and H. Nawata Protein kinase C-dependent increase in reactive oxygen species (ROS) production in vascular tissues of diabetes: role of vascular NAD(P)H oxidase J. Am. Soc. Nephrol. 14 2003 S227 S232
17. K. Irita, I. Fujita, K. Takeshige, S. Minakami, and J. Yoshitake Calcium channel antagonist induced inhibition of superoxide production in human neutrophils. Mechanisms independent of antagonizing calcium influx Biochem. Pharmacol. 35 1986 3465 3471
18. M. Kitakaze, H. Asanuma, S. Takashima, T. Minamino, Y. Ueda, Y. Sakata, M. Asakura, S. Sanada, T. Kuzuya, and M. Hori Nifedipine-induced coronary vasodilation in ischemic hearts is attributable to bradykinin- and NO-dependent mechanisms in dogs Circulation 101 2000 311 317
19. H. Lenasi, K. Kohlstedt, B. Fichtlscherer, A. Mulsch, R. Busse, and I. Fleming Amlodipine activates the endothelial nitric oxide synthase by altering phosphorylation on ser1177 and thr495 Cardiovasc. Res. 59 2003 844 853
20. J.M. Li, and A.M. Shah Mechanism of endothelial cell NADPH oxidase activation by angiotensin: II. Role of the p47phox subunit J. Biol. Chem. 278 2003 12094 12100
21. Y. Li, H. Zhu, P. Kuppusamy, V. Roubaud, J.L. Zweier, and M.A. Trush Validation of lucigenin (bis-n-methylacridinium) as a chemilumigenic probe for detecting superoxide anion radical production by enzymatic and cellular systems J. Biol. Chem. 273 1998 2015 2023
22. S. Llorens, and E. Nava Cardiovascular diseases and the nitric oxide pathway Curr. Vasc. Pharmacol. 1 2003 335 346
23. C. Napoli, V. Sica, F. de Nigris, O. Pignalosa, M. Condorelli, L.J. Ignarro, and A. Liguori Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension Am. Heart J. 148 2004 e5
24. T. Nishikawa, D. Edelstein, X.L. Du, S. Yamagishi, T. Matsumura, Y. Kaneda, M.A. Yorek, D. Beebe, P.J. Oates, H.P. Hammes, I. Giardino, and M. Brownlee Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage Nature 404 2000 787 790
25. R.A. Oeckler, P.M. Kaminski, and M.S. Wolin Stretch enhances contraction of bovine coronary arteries via an NAD(P)H oxidase-mediated activation of the extracellular signal-regulated kinase mitogen-activated protein kinase cascade Circ. Res. 92 2003 23 31
26. M.E. Oriz, L.J. Nunez-Vergara, and J.A. Squella Relative reactivity of dihydropyridine derivatives to electrogenerated superoxide ion in DMSO solutions: a voltammetric approach Pharm. Res. 20 2003 292 296
27. A.C. Rosenkranz, S.G. Hood, R.L. Woods, G.J. Dusting, and R.H. Ritchie B-type natriuretic peptide prevents acute hypertrophic responses in the diabetic rat heart: importance of cyclic GMP Diabetes 52 2003 2389 2395
28. 2+ blockers prevent myocardial remodeling induced by chronic NO inhibition in rats Hypertension 41 2003 963 967
29. C. Sand, S.L. Peters, M. Pfaffendorf, and P.A. van Zwieten Oxidative stress impairs the haemodynamic activity of cardiovascular agents with antioxidant properties Naunyn-Schmiedeberg's Arch. Pharmacol. 364 2001 454 461
30. A.W. Scribner, J. Loscalzo, and C. Napoli The effect of angiotensin-converting enzyme inhibition on endothelial function and oxidant stress Eur. J. Pharmacol. 482 2003 95 99
31. H. Takaishi, T. Taniguchi, A. Takahashi, Y. Ishikawa, and M. Yokoyama High glucose accelerates MCP-1 production via p38 MAPK in vascular endothelial cells Biochem. Biophys. Res. Commun. 305 2003 122 128
32. X. Xin, Z.A. Khan, S. Chen, and S. Chakrabarti Extracellular signal-regulated kinase (ERK) in glucose-induced and endothelin-mediated fibronectin synthesis Lab. Invest. 84 2004 1451 1459
33. S. Yamagishi, Y. Inagaki, and S. Kikuchi Nifedipine inhibits tumor necrosis factor-alpha-induced monocyte chemoattractant protein-1 overexpression by blocking NADPH oxidase-mediated reactive oxygen species generation Drugs Exp. Clin. Res. 29 2003 147 152
34. K. Yasunari, K. Maeda, T. Watanabe, M. Nakamura, A. Asada, and J. Yoshikawa Converting enzyme inhibitor temocaprilat prevents high glucose-mediated suppression of human aortic endothelial cell proliferation J. Cardiovasc. Pharmacol. 42 Suppl. 1 2003 S55 S60
35. T. Yu, I. Morita, K. Shimokado, T. Iwai, and M. Yoshida Amlodipine modulates THP-1 cell adhesion to vascular endothelium via inhibition of protein kinase C signal transduction Hypertension 42 2003 329 334
36. X. Zhang, X. Xu, A. Nasjletti, and T.H. Hintze Amlodipine enhances NO production induced by an ACE inhibitor through a kinin-mediated mechanism in canine coronary microvessels J. Cardiovasc. Pharmacol. 35 2000 195 202
37. X.P. Zhang, K.E. Loke, S. Mital, S. Chahwala, and T.H. Hintze Paradoxical release of nitric oxide by an L-type calcium channel antagonist, the R+ enantiomer of amlodipine J. Cardiovasc. Pharmacol. 39 2002 208 214